Trial Testing MS1819 Plus PERT for Exocrine Pancreatic Insufficiency Now Dosing in Turkey
cystic fibrosis, News
A clinical trial testing AzurRx BioPharma‘s investigational therapy MS1819, in combination with the current standard care for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients with cystic ... Read more